Compare Adaptive Biotechnologies Corp (ADPT) vs Berkshire Hathaway Inc Class B (BRK.B) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Berkshire Hathaway Inc Class B — how do they compare? Adaptive Biotechnologies Corp trades at $20.25 (market cap $3.33B), while Berkshire Hathaway Inc Class B trades at $496.83. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, Berkshire Hathaway Inc Class B nearer its low. Which is the better fit depends on your goals.
| ADPT | BRK.B | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | Financials |
52-Week High | $22.37 | $513.70 |
52-Week Low | $10.24 | $459.10 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
BRK.B trades at $497.5, down 1.82% today, with a bullish technical signal from moving averages and strong trend momentum (ADX). Analyst consensus is positive with 57% buy ratings and no sell recommendations. Support is firm near $494, while resistance lies at $509.
The outlook remains favorable given analyst support and technical strength, but risks include market volatility and overbought short-term conditions. Earnings growth and valuation metrics are key for sustained upside, though the stock faces macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Berkshire Hathaway Inc Class B
Berkshire Hathaway is a holding company with diverse subsidiaries, primarily in insurance through Geico and its reinsurance groups. It reinvests profits into various industries, owning Burlington Northern Santa Fe (railroad), Berkshire Hathaway Energy, and major manufacturing, service, and retail businesses like Precision Castparts and Lubrizol. The company operates in a highly decentralized manner.
Read more on BRK.B →
